Levi & Korsinsky notifies investors that it has commenced an investigation into Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) concerning potential violations of the federal securities laws.
On November 6, 2024, Amphastar received a secondary complete response letter (CRL) from the Food and Drug Administration (FDA) for its generic teriparatide ANDA, AMP-015, following months of delays surrounding the submission of the drug. Analysts expressed disappointment at the Company’s announcement and Amphastar has still not responded to the CRL. Following this news, Amphastar’s stock price fell by $7.31 per share, or approximately 13% to close at $46.09 per share on November 7, 2024.
If you suffered a loss on your Amphastar Pharmaceuticals, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure





